Moderate-risk patients with diabetes treated with a sulfonylurea appear to be at a higher risk of major adverse cardiovascular events than those who receive a dipeptidyl peptidase-4 (DPP-4) inhibitor, ...

Among adults with type 2 diabetes who started noninsulin second-line therapy, most modified treatment within 1 year. Discontinuation was by far the most common modification. Objectives: To describe ...

Background and goal: Sulfonylureas are a class of oral medications used to manage blood glucose levels in patients with type 2 diabetes. These drugs increase insulin production regardless of blood ...

A study comparing commonly used medications for type 2 diabetes has found that sulfonylurea drugs are associated with a reduced risk of out-of-hospital cardiac arrest compared with metformin. The ...

Almost 500 million adults around the world are living with type 2 diabetes, and over 200 million of those take metformin, an oral medication that reduces blood sugar (glucose) levels. Despite ...

Coverage from the 73rd Scientific Sessions of the American Diabetes Association. It’s too soon to write an epitaph for sulfonylureas as a second-line therapy with metformin, given the large number of ...

Almost two fifths of people with type 2 diabetes discontinue their second-line medication within a year of starting, reveals an analysis that suggests the risk may be the greatest with glucagon-like ...

Diabetics who were prescribed newer medications to control their illness were more likely to take these drugs as instructed than were other patients who were prescribed drugs that have been on the ...